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Osteoarthritis (OA) is the most frequent age-related joint disease affecting all tissues 2 in the joint (1). The incidence and prevalence of the disease are increased with 3 specific risk factors (2), with overweight and trauma at the forefront. These 2 risk 4 factors may be involved in the pathophysiology of the disease by specific and 5 independent pathways. Trauma and overweight on weight-bearing joints provoke 6 local biomechanical stresses; however, recent studies suggest that a low-grade 7 systemic inflammation process may be involved in some cases such as hand OA, in 8 which obesity increases the risk by two-fold (3, 4). More recently, epidemiological 9 studies have suggested that the OA risk increases with the number of cardio-10 metabolic factors, including type 2 diabetes mellitus (DM) (5-8). Moreover, DM 11 independently alters the prognosis by increasing the risk of total joint replacement (9) 12 and could be a specific OA risk factor (10, 11). 13
The inflammatory status of OA joint tissues in the setting of DM has never been 14 investigated. Overall, explanations regarding any links between DM and OA remain 15 scarce. Streptozotocin-induced diabetic rats with insulin deficiency and severe 16 hyperglycemia showed progressive loss of type II collagen and proteoglycans in 17 cartilage (12). At the molecular level, both diseases feature increased content of 18 interleukin 1β (IL-1β) along with other low-grade inflammatory mediators such as IL-19 6, IL-8, prostaglandin E 2 (PGE 2 ) as well as reactive oxygen species (ROS) . 20
Despite the role of glucose in energy metabolism in all cell types, including 21 chondrocytes (13, 14), high glucose concentration may have a detrimental effect per 22 se because excessive intracellular glucose concentration can saturate the glycolytic 23 pathway, thereby activating other secondary pathways involved in glucose 24 metabolism such as polyol, hexosamine, protein kinase C or pentose phosphate 25 M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 2 pathways and producing advanced glycation end products (AGEs) (15). All these 26 pathways are responsible for inducing oxidative stress, also incriminated in the OA 27 process (16) . Increased ROS production generated by a high-glucose environment is 28 linked to mitochondrial dysfunction, which may affect cartilage homeostasis (16) (17) (18) (19) (20) . 29
Nitric oxide (NO), the main nitrogen active species known to have pro-inflammatory 30 and pro-degradative effects on chondrocytes, has been implicated in the 31 pathophysiology of both DM and OA (21-23). 32
Finally, OA chondrocytes exposed to high glucose were found unable to down 33 regulate the glucose transporter 1 (GLUT-1), one of the main glucose transporters 34 expressed in chondrocytes, which led to enhanced glucose uptake and ROS 35 generation (24). However, the role of high extracellular glucose level on activation of 36 articular chondrocytes has never been investigated. 37
To further elucidate the link between DM, chronic hyperglycemia and OA, we aimed 38 to 1) characterize the inflammatory profile of human OA cartilage in patients with and 39 without type 2 DM and 2) investigate the effect and mechanism of action of high 40 glucose on chondrocyte activation. 41
42

METHODS 43
Collection of OA human cartilage 44
Human OA knee explants were obtained from patients undergoing total joint 45 replacement because of OA at Saint-Antoine Hospital (Paris) shortly after surgery. 46
Informed consent for the use of tissue and clinical data was obtained from each 47 patient before surgery. Experiments with human samples were approved by a French 48 institutional review board (Comité de Protection des Personnes, Paris Ile de France 49 5). The diagnosis of knee OA was based on the American College of Rheumatology 50 M A N U S C R I P T
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3 criteria (25). We pre-operatively screened patients about their diabetic status using 51 the medical file, drugs prescription, and patient interview. For each diabetic patient 52 included, we matched a non-diabetic patient undergoing total joint replacement 53 because of OA by age and body mass index (BMI), to avoid confounding factors. All 54 explants from each patient were manually dissected from all remaining cartilage 55 zones (i.e., tibial plateaus and femoral condyles) and mixed to obtain homogenous 56 isolated cartilage samples and managed as previously described (26). Briefly, the 57 cartilage explants were cut into small pieces (~5 mm 3 ), washed several times with 58 phosphate buffered saline (PBS) and incubated in DMEM culture medium containing 59 25 mM glucose necessary for human explant maintenance, and supplemented with 60 100 U/mL penicillin, 100 µg/mL streptomycin, and 4 mM glutamine for 24 h at 37°C 61 with or without IL-1β (5 ng/mL). Conditioned media (CM) were then collected, 62 centrifuged (1600 g for 6 min) and stored at -20°C. Each volume of medium was 63 normalized to wet weight of explants (6 mL/ g tissue) (27). 64 65
Primary culture of murine articular chondrocytes 66
Mouse primary chondrocytes were isolated from articular cartilage of 5-to 6-day-old 67 newborn C57Bl6 mice from Janvier (St Berthevin, France) and seeded at 8 x 10 3 68 cells per cm as described (28). Articular chondrocytes obtained from newborn mice 69 using this protocol are considered as relevant to study mature chondrocytes since 70 type II collagen and aggrecan mRNA levels are highly expressed while expression of 71 type I collagen mRNA expression remains low (29). After 1 week of amplification in 72 DMEM with 5.5 mM glucose, cells were incubated in serum-free DMEM (with 5.5 mM 73 glucose) containing 0.1% bovine serum albumin (BSA) for 24 h before treatment 74 (basal experimental medium). Each litter of mice was used for one experiment. All 75 M A N U S C R I P T 
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Treatment of primary culture of murine chondrocytes 80
After 24-h incubation in basal experimental medium, murine chondrocytes were 81 stimulated for 24 or 72 h with IL-1β (5 ng/mL) (PeproTech, Rocky Hill, NJ, USA) 82 under normal-glucose (5.5 mM) or high-glucose (25 mM) conditions. Cell lysates 83
were collected for mRNA extractions and supernatants for assays. The dose of IL-1β 84 was considered efficient after a dose-effect experiment (data not shown). 85
To investigate whether the effect of high glucose was related to its osmotic effect, 86 cells were incubated with mannitol (19.5 mM) (Sigma-Aldrich, Lyon, France) instead 87 of glucose (25 mM) for 24 and 72 h, with or without IL-1β (5 ng/mL) in 4 separate 88
experiments. 89
For mechanistic studies, chondrocytes cultured with normal or high glucose for 72 h 90 with or without IL-1β (5 ng/mL) were pretreated or treated with inhibitors: cytochalasin 91 Because human OA cartilage explants from DM patients showed a stronger 209 inflammatory phenotype than non-DM cartilage especially after IL-1β stimulation, we 210 speculated that sustained extracellular high glucose exposure could be one of the 211 actors in this responsiveness. Thus, we explored in vitro the mechanistic impact of 212 high glucose on murine chondrocyte activation induced by IL-1β. Murine cells were 213 treated or not with IL-1β (5 ng/mL) for 24 or 72 h with normal glucose (5.5 mM) or 214 high glucose (25 mM) (Figure 2) . As expected, IL-1β increased IL-6 mRNA 215 expression and protein release as well as COX2 mRNA expression and PGE 2 216 release, regardless of glucose concentration (Figure 2A and 2B ). However, with IL-217 1β stimulation at 72 h, IL-6 mRNA and protein levels and PGE 2 release were higher 218 with high than normal glucose (4-to 7-fold increase). At 24 h with IL-1β stimulation, 219 IL-6 mRNA and protein levels and PGE 2 release were higher but not significantly, 220 except for COX2 expression which was significantly higher with high than normal 221 glucose. Conversely, high glucose alone (without IL-1β stimulation) did not change As a control experiment, we first measured glucose uptake in murine chondrocytes 231 by using 2-deoxyglucose, a non-metabolized analogue of glucose, with the same 232 experimental schedule (Figure 3A) . At 24 h, and even more so at 72 h, glucose 233 uptake was increased with IL-1β treatment under normal-glucose conditions. 234
Additionally, high glucose further increased glucose uptake, which was at its peak 235 rate at 72 h (p for trend = 0.12). Changes in glucose concentration without IL-1β 236 moderately changed glucose uptake, which suggests a role for IL-1β in glucose 237 transport variation. 238
To analyse the possibility that the effect of high glucose level was due to osmotic 239 stress, we replaced glucose excess (19.5 mM) by mannitol at the same molar 240 concentration, as a control for the hyperosmotic effects of high glucose level ( Figure  241 3B). Chondrocytes stimulated with IL-1β in the presence of mannitol released 242 amounts of IL-6 similar to that under normal glucose conditions (p=0.12) at 24 and 72 243 h, but we found a trend for a difference between expression under high glucose and 244 mannitol (p=0.06). Therefore, we could rule out the impact of osmotic stress in the 245 pro-inflammatory effect of high glucose environment. 246
To determine the direct role of glucose uptake, cells were pre-treated for 30 min with 247 cytochalasin B (1 µM), a glucose transport inhibitor (Figure 4A) , and IL-6 release 248 Figure S1) . 266 267
High glucose increases the oxidative stress induced by IL-1β 268
To determine whether excess glucose may potentiate chondrocyte activation by 269 producing ROS and reactive nitrogen species, we measured the production of ROS 270 by fluorescent DCFDA (Figure 5A ) and NBT (Figure 5B ) and the production of (Figures 5A and B) . IL-1β stimulated nitrite production whatever the glucose 275 concentration at 24 and 72 h (Figure 5C ). Interestingly, with IL-1β stimulation, nitrite 276 generation was significantly higher under high-than normal-glucose conditions, 277 especially at 72 h. These results stressed the role of IL-1β and high glucose 278
combined in the formation of oxidative stress derivatives. 279
To investigate whether these findings could be responsible for the pro-inflammatory 280 effect in chondrocytes, cells were treated with MitoTEMPO (50 µM), a specific 281 mitochondrial ROS scavenger, or L-NAME (5 mM), an inhibitor of NO-synthase. LDH 282 measurement revealed no cytotoxic effects at these concentrations (data not shown). 283
Under normal glucose, neither MitoTEMPO nor L-NAME modified IL-1β-increased IL-284 6 production (Figures 6A and 6D) . However, under high glucose, IL-1β-increased IL-285 6 production was inhibited with MitoTEMPO (-40%, p=0.06) and L-NAME (-38%; 286 p<0.05). In addition, L-NAME but not MitoTempo could inhibit IL-1β-increased PGE 2 287 production under high glucose (-78%; p<0.05) (Supplementary Figure S2) . To understand the epidemiological link between diabetes mellitus and OA, we 291 phenotyped OA cartilage from diabetic and non-diabetic patients according to 292 responsiveness to IL-1β-induced inflammatory stress, as assessed by IL-6 and PGE 2 293 release. Such increased reactivity was corroborated by sensitization of articular 294 chondrocytes to a high-glucose environment with IL-1β stimulation. This enhanced 295 pro-inflammatory response under high glucose conditions was related, at least in 296 part, to increased glucose uptake, oxidative stress and activation of the polyol 297 pathway and resulted in a sustained chondrocytic pro-inflammatory phenotype 298 (Figure 7) . 299
First, we aimed to assess the spontaneous release of IL-6 and PGE 2 by human 300 cartilage from diabetic versus non-diabetic patients exposed to a high glucose level 301 in the years before arthroplasty. And, because the low-grade inflammation observed 302 in type 2 DM and OA involves IL-1β, we investigated the inflammatory response of 303 diabetic and non-diabetic OA cartilage to IL-1β. We carefully selected OA cartilage 304 explants from humans matched on age and BMI to diabetic patients and found no 305 differences in sex ratio and other metabolic co-morbidities. All diabetic patients 306 received at least one anti-diabetic therapy. Unfortunately, we could not analyse the 307 role of specific drugs because of lack of statistical power. The mean values of HbA1c 308 fraction in our patients reflects a good glycemia control for the last 3 months before 309 surgery, but does not reflect all the diabetes history and not preclude previous 310 uncontrolled DM periods with chronic hyperglycemia. Finally, cartilage was not 311 histologically scored, but because all patients underwent total knee replacement, we 312 assume that OA tissular lesions were at an advanced stage in all cases.
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In vitro, we demonstrated increased glucose uptake by articular chondrocytes under 314 a high-glucose condition, especially with IL-1β stimulation. IL-1β was already found 315 to increase the synthesis of the inducible glucose transporters GLUT-1 and -9 in 316 articular chondrocytes (30). We found similar results for GLUT-1 (data not shown). 317
Thus, under normal-glucose conditions, glucose uptake was moderately stimulated 318 by IL-1β, despite IL-1β-increased expression of GLUT-1. This uptake was markedly 319 increased when cells were cultured under high-glucose conditions. Treating articular 320 chondrocytes with cytochalasin B abolished the additive pro-inflammatory effect of 321 high glucose in IL-1-β-stimulated chondrocytes, which confirms the role of glucose 322 uptake in chondrocyte activation. Although cytochalasin B is usually used as a 323 glucose transport inhibitor (31), this compound can be responsible for damages of 324 the microfilament network, and thus can alter mechanical environment of the cell. 325
However, we first can observe that cytochalasin B treatment in normal glucose 326 condition, under IL-1β stimulation, has no effect on IL-6 production, suggesting that 327 cytochalasin B reverses specifically the potentiating effect of high glucose. Second, 328
2DG* experiments have confirmed that, concomitantly to chondrocytes activation, 329 there is an increased glucose entrance in high glucose condition in presence of IL-330 1β. We then can speculate that the effect of cytochalasin B is related here to glucose 331 uptake effect, not to a global disruption of the microfilament network. 332
Under high-glucose conditions, the glycolytic pathway may be saturated, for 333 increased flux of available glucose through the alternative polyol pathway (15). 334
Increased activity of the polyol pathway, which occurs especially when the glycolytic To 339 that end, we treated articular chondrocytes with epalrestat, a specific inhibitor of 340 aldose reductase, which has had promising results in preventing neuropathy 341 progression and is currently used in Japan as an oral drug in clinical practice for this 342 complication (36-38). We found a significant inhibition of the potentiating effect of 343 high glucose for both IL-6 and PGE 2 production. The production of both mediators 344 was decreased to a lesser extent under normal glucose conditions when 345 chondrocytes were treated with epalrestat, which suggests that the polyol pathway 346 may participate in IL-1β stimulation of chondrocytes by high glucose. 347
Finally, we studied the impact of high-glucose conditions on direct synthesis of ROS 348 by articular chondrocytes using 2 different methods, as well as its potentiating effect 349 on NO production induced by IL-1β. At 72h, IL-1β behaved differently under high and 350
normal glucose conditions and may be responsible for early oxidative stress only 351 under high glucose, for subsequent IL-6 production. 352
We used the antioxidant MitoTEMPO and an inhibitor of NO-synthase, L-NAME. In 353 healthy chondrocytes, the production of energy from glucose metabolism is mainly 354 from the glycolytic pathway and mitochondria are poorly solicited (39). In a pro-355 inflammatory and high-glucose environment, the mitochondrial respiratory chain 356 could be more activated and thus increase mitochondrial ROS production. Moreover, 357 superoxide ion (O 2°-), mainly produced by mitochondria, is the main product 358 responsible for the formation of other ROS (19). Thus, we treated chondrocytes with 359 a specific scavenger of mitochondrial ROS, MitoTEMPO, and found inhibition of IL-6 360 production (p=0.06), which supports that ROS production induced by high glucose 361
was responsible at least in part for the production of pro-inflammatory mediators. 362
Additionally, the use of the inhibitor L-NAME suggested the involvement of NO in the M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 16 potentiating effect of high glucose in pro-inflammatory effects because we found a 364 significant inhibition of IL-6 and PGE 2 production. 365
Excessive production of both superoxyde ion and NO can lead to peroxynitrite 366 formation, an extremely reactive compound responsible for DNA lesions and lipid 367 peroxidation and thus deleterious for tissues (40, 41) . This molecule is involved in a 368 wide range of diseases, including diabetes and OA (42, 43) . 369
This study has some limitations. First, in our human study, we cannot exclude that 370 some patients from the non-diabetic group were undiagnosed. However, including 371 diabetic patients in the non-diabetic group may underestimate the difference in 372 release of inflammatory mediators. 373
Second, we performed our mechanistic experiments on primary cultures of murine 374 but not human chondrocytes. Indeed, to investigate the effect of glucose and/or IL-1β 375 on chondrocyte activation, we needed to use normal chondrocytes to rule out the 376 potential impact of diabetic status. Because of the challenge in obtaining normal 377 human cartilage explants, we used murine cells. We previously compared the 378 phenotype of murine and human chondrocytes and showed that the main markers of 379 differentiation were similar (28-29). Moreover, the similarity in terms of IL-6 and PGE 2 380 release by IL-1β-stimulated murine chondrocytes under high glucose and by diabetic 381 cartilage explants strengthen the use of murine cells for mechanistic experiments. 382
Finally, we investigated some pathways involved in the molecular consequences of 383 glucose excess (i.e., ROS, glucose uptake, polyol pathway). However, glucose may 384 also act through numerous other pathways such as the hexosamine pathway, protein 385 kinase C activation or the production of AGEs, also involved in the glucotoxicity 386 process seen in DM, but not explored in the present study (15). ROS blockade and 387 polyol inhibition could prevent reactivity to high glucose, which illustrates their crucial 388 M A N U S C R I P T
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role in chondrocyte activation due to hyperglycemia. While the use of antioxidants 389 has led to deceptive results in OA, epalrestat may be useful in this articular 390 complication of diabetes. The enhanced degradation of extracellular matrix by the 391 polyol pathway in intervertebral discs of diabetic rats supports such a hypothesis 392 (44). 393
Moreover, beyond the effect of high glucose, other molecules might be involved to 394 explain higher responsiveness of human cartilage form diabetic patients to 395 inflammatory stress. Indeed, type 2 DM is characterized by hyperglycemia, 396 hyperinsulinemia with insulin resistance and free fatty acids increase (45, 46). Some 397 studies have examined the role of insulin in joint tissues and have shown an anabolic 398 role of this hormone with the induction of the synthesis of type II collagen and 399 proteoglycans by chondrocytes (47-49). However, the effect of insulin on joint cells 400 and tissues or of insulin resistance in OA needs to be addressed. Activity of the 401 insulin receptor was found lower in human OA than healthy chondrocytes, which 402 limits the beneficial effects of this hormone on cells during OA (50). 403
In conclusion, OA cartilages from diabetic patients are more reactive than non-404 diabetic to pro-inflammatory stress, thus displaying an inflammatory phenotype. This 405 phenotype may be due to glucotoxicity combined with IL1-β stress and then 406 responsible for sustained inflammatory chondrocyte activation involving increased 407 GLUT expression, glucose uptake, oxidative stress and the polyol pathway. These 408 results strengthen the hypothesis that diabetes could be a trigger for the initiation 409 
